["crohn's disease"]
['mirikizumab', 'placebo']

        Inclusion Criteria:

          -  Active Crohn's Disease (CD) as determined by the SES-CD, and participant reported
             stool frequency and abdominal pain.

          -  Inadequate response or failure to tolerate at least one of the following:
             aminosalicylates; budesonide; systemic corticosteroids; immunosuppressants (eg,
             azathioprine, 6-mercaptopurine, or methotrexate); or prior exposure to biologics for
             the treatment of CD.

        Exclusion Criteria:

          -  Have complications of CD such as strictures, stenoses, or any other manifestation for
             which surgery might be indicated, or that could confound the evaluation of efficacy.

          -  Diagnosis of conditions affecting the digestive tract, such as ulcerative colitis,
             indeterminate colitis, fistulizing disease, abdominal or perianal abscess, adenomatous
             colonic polyps not excised, colonic mucosal dysplasia, and short bowel syndrome.

          -  Have had any kind of bowel resection, diversion, or placement of a stoma within 6
             months or any other intra-abdominal surgery within 3 months prior to screening.

          -  Are unsuitable for inclusion in the study in the opinion of the investigator or
             sponsor for any reason that may compromise the subject's safety or confound data
             interpretation.
      